Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the chronic pulmonary hypertension treatment market size evolved in recent years?
The market size for treating chronic pulmonary hypertension has seen impressive growth in the recent past. It is expected to increase from $6.82 billion in 2024 to $7.21 billion in 2025, marking a compound annual growth rate (CAGR) of 5.8%. Factors such as the escalating number of chronic pulmonary hypertension cases, an upsurge in drug approvals, beneficial reimbursement procedures, elevated healthcare spending, and an aging population contribute to the progress observed during the historic period.
What are the predictions for the chronic pulmonary hypertension treatment market size in the coming years?
The market for treatment of chronic pulmonary hypertension is poised for robust expansion in the coming years. By 2029, the market is projected to reach a valuation of $8.95 billion, growing at a Compound Annual Growth Rate (CAGR) of 5.6%. This projected expansion during the forecasted period is attributed to a surge in demand for potent treatments, escalated investments, augmented government backing for drug development, increasing demand for advanced therapeutics, growing awareness, and a rising occurrence of chronic brain injuries. Key trends expected during the forecast period encompass new drug and therapy development, technological advancements, collaborations with pharmaceutical companies, research institutions, and healthcare organizations, discovery of new molecular pathways, government and healthcare organizational investment, and innovation in therapy.
Get your chronic pulmonary hypertension treatment market report here!
What key factors are fueling the growth of the chronic pulmonary hypertension treatment market?
The escalating prevalence of cardiovascular disorders is anticipated to trigger the expansion of the chronic pulmonary hypertension treatment market in future. These disorders consist of an array of conditions impacting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The elevated prevalence of these diseases is largely caused by risk elements such as improper eating habits, lack of physical activity, tobacco usage, alcohol abuse, obesity, hypertension, diabetes, and an aging demographic. The treatment for chronic pulmonary hypertension proves beneficial for cardiovascular health as it decreases pulmonary artery pressure, boosts heart function, and mitigates the threat of heart failure and associated issues. For example, as per the Australian Institute of Health and Welfare, a government agency based in Australia, in December 2023, there were 14,100 deaths confirmed by doctors due to coronary heart disease (CHD) in 2021, increasing to 14,900 in 2022. Consequently, the rising prevalence of cardiovascular diseases is influencing the growth of the chronic pulmonary hypertension treatment market.
How is the global chronic pulmonary hypertension treatment market divided into key segments?
The chronic pulmonary hypertension treatment market covered in this report is segmented –
1) By Drug Type: Endothelin Receptor Antagonists, Phosphodiesterase (PDE-5) Inhibitors, Prostacyclin Analogs, Soluble Guanylate Cyclase (SGC) Stimulators
2) By Route Of Administration: Oral, Intravenous Or Subcutaneous, Inhalational
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Endothelin Receptor Antagonists: Bosentan, Ambrisentan, Macitentan
2) By Phosphodiesterase (PDE-5) Inhibitors: Sildenafil, Tadalafil, Vardenafil
3) By Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost
4) By Soluble Guanylate Cyclase (SGC) Stimulators: Riociguat
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21148&type=smp
Who are the key firms paving the way for growth in the chronic pulmonary hypertension treatment market?
Major companies operating in the chronic pulmonary hypertension treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi SA, AstraZeneca PLC, Novartis AG, GSK (GlaxoSmithKline), Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Insmed, Cereno Scientific, Roivant Sciences, LGM Pharma, Liquidia Technologies
How are evolving market trends shaping chronic pulmonary hypertension treatment Strategies?
Leading corporations in the chronic pulmonary hypertension treatment sector are now concentrating on developing innovative solutions like subcutaneous injection. This approach is geared towards improving patient adherence, enhancing convenience, and offering more specific treatment options. Subcutaneous injection provides medication constantly under the skin, beneficial in reducing pulmonary artery pressure and bettering blood flow in those suffering from pulmonary hypertension. For example, in March 2024, Merck & Co Inc., an American pharmaceutical company, revealed that the U.S. Food and Drug Administration (FDA) had given its approval for Winrevair (sotatercept-csrk) – a commendable progression in the treatment of pulmonary arterial hypertension (PAH). This revolutionary therapy provides unique advantages, thereby establishing it as a pioneering treatment option for PAH. Clinical studies highlight that Winrevair enhances the WHO functional class in 29% of patients, in contrast to the 14% observed among those on placebo, thus leading to an overall improvement in life quality.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21148
What regions are contributing significantly to the growth of the chronic pulmonary hypertension treatment market?
North America was the largest region in the chronic pulmonary hypertension treatment market in 2024. The regions covered in the chronic pulmonary hypertension treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Convalescent Plasma Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report
Plasma Fractionation Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report
Negative Pressure Wound Therapy Global Market Report 2025
https://thebusinessresearchcompany.com/report/negative-pressure-wound-therapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
